Previous close | 2.1700 |
Open | 2.2000 |
Bid | 2.0900 x 100 |
Ask | 2.2100 x 100 |
Day's range | 2.0800 - 2.2500 |
52-week range | 1.4000 - 7.7500 |
Volume | |
Avg. volume | 253,221 |
Market cap | 57.28M |
Beta (5Y monthly) | 0.05 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.8900 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 14.00 |
European Orphan Drug Designation (“ODD”) qualifies NXC-201 for: 10 years of market exclusivity once authorized in the EUAccess to the EU centralized authorization procedureReduced fees for: EU protocol assistance, marketing authorization applications, inspections before authorization, applications for changes to marketing authorizations made after approval, and reduced annual fees LOS ANGELES, April 29, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Immix Biopharma”, “Company”, “We” or “Us”, N
Scheduling U.S. site initiation visits April and May 2024On track to dose relapsed/refractory AL Amyloidosis patients with CAR-T NXC-201 at New York City lead site and other leading U.S. sites mid-2024 No change in patient enrollment timing LOS ANGELES, April 18, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and other autoimmune diseases, today
Updated clinical data for next-generation CAR-T NXC-201 in relapsed/refractory AL amyloidosis will be presented in Baltimore May 7-11, 2024 LOS ANGELES, April 15, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and other autoimmune diseases, today announced that updated NXC-201 clinical data has been selected for presentation at the upcoming 27th